|
Travere Therapeutics, Inc. (TVTX) Évaluation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Travere Therapeutics, Inc. (TVTX) Bundle
Gardez un aperçu de votre analyse d'évaluation de votre Travere Therapeutics, Inc. (TVTX) à l'aide de notre calculatrice sophistiquée DCF! Ce modèle Excel est préchargé avec des données réelles (TVTX), vous permettant d'ajuster les prévisions et les hypothèses pour un calcul précis de la valeur intrinsèque de Travere Therapeutics.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 198.3 | 227.5 | 212.0 | 145.2 | 233.2 | 254.7 | 278.3 | 304.0 | 332.0 | 362.7 |
| Revenue Growth, % | 0 | 14.71 | -6.8 | -31.5 | 60.55 | 9.24 | 9.24 | 9.24 | 9.24 | 9.24 |
| EBITDA | -144.0 | -186.7 | -299.4 | -326.2 | -265.8 | -231.6 | -253.0 | -276.4 | -301.9 | -329.8 |
| EBITDA, % | -72.59 | -82.06 | -141.22 | -224.63 | -113.98 | -90.93 | -90.93 | -90.93 | -90.93 | -90.93 |
| Depreciation | 25.8 | 26.6 | 20.7 | 38.5 | 43.6 | 40.6 | 44.3 | 48.4 | 52.9 | 57.8 |
| Depreciation, % | 13 | 11.7 | 9.77 | 26.53 | 18.68 | 15.94 | 15.94 | 15.94 | 15.94 | 15.94 |
| EBIT | -169.7 | -213.3 | -320.1 | -364.8 | -309.3 | -244.2 | -266.8 | -291.4 | -318.3 | -347.7 |
| EBIT, % | -85.59 | -93.76 | -151 | -251.16 | -132.66 | -95.87 | -95.87 | -95.87 | -95.87 | -95.87 |
| Total Cash | 361.6 | 552.9 | 450.2 | 566.9 | 370.7 | 254.7 | 278.3 | 304.0 | 332.0 | 362.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 33.1 | 15.9 | 16.6 | 21.2 | 27.1 | 29.4 | 32.1 | 35.1 | 38.3 | 41.9 |
| Account Receivables, % | 16.67 | 7 | 7.85 | 14.58 | 11.63 | 11.55 | 11.55 | 11.55 | 11.55 | 11.55 |
| Inventories | 7.6 | 7.3 | 6.9 | 9.4 | 6.2 | 9.9 | 10.8 | 11.8 | 12.9 | 14.1 |
| Inventories, % | 3.84 | 3.21 | 3.26 | 6.48 | 2.66 | 3.89 | 3.89 | 3.89 | 3.89 | 3.89 |
| Accounts Payable | 12.1 | 15.1 | 17.3 | 41.7 | 23.5 | 30.4 | 33.2 | 36.3 | 39.7 | 43.3 |
| Accounts Payable, % | 6.12 | 6.66 | 8.15 | 28.69 | 10.09 | 11.94 | 11.94 | 11.94 | 11.94 | 11.94 |
| Capital Expenditure | -119.8 | -24.2 | -28.6 | -.7 | -101.2 | -65.4 | -71.4 | -78.0 | -85.3 | -93.1 |
| Capital Expenditure, % | -60.43 | -10.62 | -13.47 | -0.45993 | -43.41 | -25.68 | -25.68 | -25.68 | -25.68 | -25.68 |
| Tax Rate, % | -0.32292 | -0.32292 | -0.32292 | -0.32292 | -0.32292 | -0.32292 | -0.32292 | -0.32292 | -0.32292 | -0.32292 |
| EBITAT | -152.3 | -213.8 | -320.5 | -108.0 | -310.3 | -204.8 | -223.7 | -244.4 | -267.0 | -291.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -274.9 | -190.9 | -326.5 | -52.8 | -388.9 | -228.7 | -251.7 | -274.9 | -300.3 | -328.1 |
| WACC, % | 6.98 | 7.09 | 7.09 | 6.33 | 7.09 | 6.92 | 6.92 | 6.92 | 6.92 | 6.92 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,123.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -335 | |||||||||
| Terminal Value | -6,804 | |||||||||
| Present Terminal Value | -4,870 | |||||||||
| Enterprise Value | -5,994 | |||||||||
| Net Debt | 343 | |||||||||
| Equity Value | -6,337 | |||||||||
| Diluted Shares Outstanding, MM | 79 | |||||||||
| Equity Value Per Share | -80.33 |
What You Will Get
- Accurate TVTX Financial Data: Pre-filled with Travere Therapeutics’ historical and projected data for detailed analysis.
- Fully Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Watch Travere Therapeutics’ intrinsic value update in real-time as you make changes.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants aiming for precise DCF results.
- User-Friendly Interface: Intuitive layout and straightforward instructions suitable for all skill levels.
Key Features
- Comprehensive TVTX Data: Pre-loaded with Travere Therapeutics' historical performance metrics and future growth estimates.
- Customizable Assumptions: Modify key inputs such as revenue forecasts, profit margins, discount rates, tax implications, and capital investments.
- Interactive Valuation Framework: Real-time adjustments to Net Present Value (NPV) and intrinsic value based on user-defined parameters.
- Scenario Analysis: Develop various forecasting scenarios to evaluate different potential valuation results.
- Intuitive Interface: Designed for ease of use, catering to both seasoned professionals and newcomers.
How It Works
- 1. Access the Template: Download and open the Excel file containing Travere Therapeutics, Inc.'s (TVTX) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Immediately: The DCF model automatically calculates intrinsic value and NPV based on your inputs.
- 4. Explore Different Scenarios: Evaluate various forecasts to assess different valuation possibilities.
- 5. Present with Assurance: Share professional valuation findings to bolster your strategic decisions.
Why Choose This Calculator for Travere Therapeutics, Inc. (TVTX)?
- Designed for Industry Experts: A sophisticated tool utilized by investors, analysts, and healthcare professionals.
- Comprehensive Data: Travere Therapeutics’ historical and projected financials included for precision.
- Flexible Scenario Analysis: Effortlessly model various forecasts and assumptions.
- Detailed Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly Interface: Step-by-step guidance ensures a smooth user experience.
Who Should Use This Product?
- Investors: Accurately estimate Travere Therapeutics’ fair value before making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Travere Therapeutics (TVTX).
- Consultants: Efficiently customize the template for valuation reports tailored to Travere Therapeutics (TVTX) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biotech firms.
- Educators: Implement it as a teaching resource to illustrate valuation methodologies in the biotech sector.
What the Template Contains
- Pre-Filled DCF Model: Travere Therapeutics, Inc.’s (TVTX) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Travere Therapeutics, Inc.’s (TVTX) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.